NCT06901245View on ClinicalTrials.gov

Tirzepatide in PWS, HO and GNSO

PHASE4RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Prader-Willi SyndromeHypothalamic ObesityObesity/Therapy
Interventions
DRUG

Tirzepatide

Subjects will take Tirzepatide for 48 weeks

Trial Locations (3)

37203

RECRUITING

Vanderbilt University Medical Center, Nashville

55102

RECRUITING

Children's Minnesota, Saint Paul

98105

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

collaborator

Children's Hospitals and Clinics of Minnesota

OTHER

collaborator

Seattle Children's Hospital

OTHER

lead

Grace Kim

OTHER